Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7927887 | 0.84 | KDM4E (0.41) | KDM4EKMT2A | |
| SCHEMBL4291393 | 0.83 | CYP1A2 (0.38) | KDM4EKMT2ACYP2D6 | |
| SCHEMBL19575870 | 0.83 | CYP1A2 (0.38) | KDM4EKMT2ACYP2D6 | |
| SCHEMBL21661391 | 0.76 | KDM4E (0.35) | KDM4EKMT2A | |
| SCHEMBL22570070 | 0.76 | — | — | |
| SCHEMBL4841589 | 0.76 | — | — | |
| SCHEMBL16422339 | 0.76 | KDM4E (0.36) | KDM4EKMT2AMAPTATMCYP2D6 | |
| SCHEMBL554873 | 0.75 | DPP9 (0.37) | KMT2A | |
| SCHEMBL14222286 | 0.74 | KDM4E (0.35) | KDM4EKMT2AMAPTATMCYP2D6 | |
| Hydrochloric Acid SCHEMBL34473679 | 0.74 | KDM4E (0.32) | KDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11332459-B2 | Benzimidazole derivatives and their uses | TEIJIN PHARMA LIMITED (JP) | 2022-05-17 | — | — | US | disclosed |
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | AMGEN INC. (US) | 2020-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200308145-A1 | BENZIMIDAZOLE DERIVATIVES AND THEIR USES | TRPC6, TRPV6, TRPM6 | KDM4E 2263/4885KMT2A 3145/4885MAPT 3674/4885 |
| US-11332459-B2 | Benzimidazole derivatives and their uses | TRPC6, TRPV6, TRPM6 | KDM4E 2263/4885KMT2A 3145/4885MAPT 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.